Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 105 participants.
Also called NCT02409238
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 105 participants
- Sponsor
- Registry
-
NCT02409238
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Singapore
- Registry status
- Terminated
Technical summary
Registry record NCT02409238. Randomized; no masking; primary purpose treatment. Start 2015-03-11 (actual); primary completion 2019-12-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study
- Acronym
- IRMCI
- Condition
- Mild Cognitive Impairment
- Condition
- Insulin Resistance
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Metformin
- Intervention (Behavioral)
- Intensive Lifestyle Intervention
- Intervention (Behavioral)
- Standard LIfestyle Recommendation
- Lead sponsor
- SingHealth Polyclinics
- Collaborator
- National University of Singapore
- Collaborator
- Singapore General Hospital
- Collaborator
- Changi General Hospital
- Collaborator
- National University Hospital, Singapore
- Collaborator
- Singapore Clinical Research Institute
- Collaborator
- Agency for Science, Technology and Research
- Collaborator
- Khoo Teck Puat Hospital
- Collaborator
- Duke-NUS Graduate Medical School
Record details
- Record id
cardio:ct-nct02409238- Content hash
70e12db1498a20f24199b3ca42241d8cf78f91213be85bb77a723e1d3792c4b1